Bryan C Barnhart
Overview
Explore the profile of Bryan C Barnhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
Cell Rep
. 2022 May;
39(7):110812.
PMID: 35568025
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs)...
2.
Cantera J, Cate D, Golden A, Peck R, Lillis L, Domingo G, et al.
ACS Omega
. 2021 Aug;
6(31):20139-20148.
PMID: 34373846
Severe acute respiratory coronavirus-2 (SARS-CoV-2) is a novel viral pathogen and therefore a challenge to accurately diagnose infection. Asymptomatic cases are common and so it is difficult to accurately identify...
3.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al.
bioRxiv
. 2021 May;
PMID: 33972947
In Brief: LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern and whose epitope is rarely mutated. Highlights: LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and known...
4.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
Sci Transl Med
. 2021 Apr;
13(593).
PMID: 33820835
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may...
5.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
bioRxiv
. 2020 Oct;
PMID: 33024963
One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.
6.
Barnhart B, Quigley M
Immunol Cell Biol
. 2016 Dec;
95(4):340-346.
PMID: 27974746
The use of antibody therapy for cancer has steadily increased in recent years and has become standard treatment for numerous tumor types. It is now appreciated that the clinical activity...
7.
Dahan R, Barnhart B, Li F, Yamniuk A, Korman A, Ravetch J
Cancer Cell
. 2016 Jun;
29(6):820-831.
PMID: 27265505
While engagement of the inhibitory Fcγ-receptor (FcγR) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement for human mAbs...
8.
Barnhart B, Lam J, Young R, Houghton P, Keith B, Simon M
Cancer Biol Ther
. 2008 Aug;
7(9):1441-9.
PMID: 18708753
Elevated activity of the eIF4F complex, which controls initiation of cap-dependent mRNA translation, has been linked to cancer progression. eIF4E recruitment to eIF4F is the rate limiting step of complex...
9.
Simon M, Liu L, Barnhart B, Young R
Annu Rev Physiol
. 2007 Sep;
70:51-71.
PMID: 17850210
Low oxygen (O2) levels are a naturally occurring feature of embryonic development, adult physiology, and diseases such as those of the cardiovascular system. Although many responses to O2 deprivation are...
10.
Barnhart B, Simon M
J Clin Invest
. 2007 Sep;
117(9):2385-8.
PMID: 17786234
Increased cap-dependent mRNA translation rates are frequently observed in human cancers. Mechanistically, many human tumors often overexpress the cap binding protein eukaryotic translation initiation factor 4E (eIF4E), leading to enhanced...